Susquehanna International Group, LLP Enlivex Therapeutics Ltd. Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 07, 2024	BUY	$2.54 - $4.3 $57,404 - $97,180	22,600 New	22,600 $85,000
Q3 2023 Nov 14, 2023	SELL	$1.46 - $2.97 $51,830 - $105,435	-35,500 Reduced 59.46%	24,200 $38,000
Q2 2023 Aug 11, 2023	SELL	$2.51 - $3.71 $131,021 - $193,662	-52,200 Reduced 46.65%	59,700 $157,000
Q1 2023 May 16, 2023	SELL	$3.41 - $4.55 $372,713 - $497,315	-109,300 Reduced 49.41%	111,900 $407,000
Q4 2022 Feb 14, 2023	SELL	$3.74 - $4.81 $269,654 - $346,801	-72,100 Reduced 24.58%	221,200 $871,000
Q3 2022 Nov 14, 2022	BUY	$4.11 - $5.87 $809,670 - $1.16 Million	197,000 Added 204.57%	293,300 $1.25 Million
Q2 2022 Aug 15, 2022	BUY	$3.81 - $8.64 $315,849 - $716,256	82,900 Added 618.66%	96,300 $435,000
Q4 2021 Feb 14, 2022	SELL	$5.81 - $9.73 $375,907 - $629,531	-64,700 Reduced 82.84%	13,400 $84,000
Q3 2021 Nov 15, 2021	BUY	$7.43 - $13.86 $182,035 - $339,570	24,500 Added 45.71%	78,100 $772,000
Q1 2021 May 17, 2021	BUY	$9.26 - $24.0 $496,336 - $1.29 Million	53,600 New	53,600 $594,000

930K

Ticker ENLV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,403,200
Market Cap $18M
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.